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Summary
The evidence that prostate cancer (PCa) express-
es specific receptors for hormones and neuropep-
tides, including somatostatin (SRIF) receptors
(SSRs) has driven the research towards the identi-
fication of new potential diagnostic/therapeutic
paths besides the conventional treatment options.
Although the first attempts has led to inconclusive
results due to the heterogeneity of this tumor and
to the complex mechanisms involved in the pro-
gression of PCa tumor growth, the potential role of
SRIF and its synthetic analogues (SSAs) in the
treatment of PCa represents an “open challenge”
in the light of the new knowledge about SSR
pathophysiology. Indeed, SRIF and SSAs can con-
trol tumor cell proliferation by two separate mech-
anisms: a direct mechanism through the activa-
tion of the five specific SSRs or an indirect mech-
anism through the inhibition of secretion of sever-
al growth factors and hormones responsible for
tumor cell proliferation. Since new SSAs specific
for each receptor subtype, as well as bi-specific
compounds and panligands have been syn-
thetized, the identification of alternative SSR tar-
gets on PCa cells and the consequent employment
of these new specific molecules in the treatment
of advanced PCa (alone or in combination with tra-
ditional treatment options), could improve the
prognosis particularly of those patients not re-
sponding to (anti-) hormonal therapy (hormone-re-
fractory PCa patients). 
KEY WORDS: somatostatin receptors, prostate, can-
cer, tumor progression, octreotide, lanreotide.
Introduction
PCa represents the second most common malignancy
after lung cancer in males (1). Since about 70% of
prostate neoplasms show an androgen-dependent
phenotype, androgen-deprivation is currently the pre-
ferred primary treatment for hormone responsive PCa.
Conversely, therapy is very limited for hormone refrac-
tory prostate cancer (HRPCa) in which neuroen-
docrine differentiation (NED) seems to play a critical
role in disease progression toward castration resist-
ance. Because chemotherapy minimally improves sur-
vival of patients with HRPCa, there is increasing inter-
est in exploring innovative therapeutic approaches
through better tolerated and effective drugs. Improved
understanding of PCa biology has led to new promis-
ing treatment strategies, in particular peptide-based
agonists and antagonists, including somatostatin
(SRIF) analogs (SSAs), alone or in combination with
other treatments (2-4). 
SRIF is a cyclic polypeptidic hormone largely ex-
pressed in hypothalamus which displays inhibitory
functions on hormone secretion (5-18) and cell prolif-
eration (14, 19, 20). SRIF acts through the binding
with five specific membrane receptors (SSRs) code-
named SS1R-5 (21). All SSRs functionally couple to G
proteins and belong to the seven-transmembrane seg-
ment receptor superfamily (22). Since SSRs mainly
exert inhibitory functions, selective agonists targeting
these receptors have been developed for the treat-
ment of a number of neuroendocrine disorders. Be-
sides pituitary, SSRs are heterogeneously expressed
in numerous normal and neoplastic tissues. Interest-
ingly, SSRs are highly expressed in PCa (23-29) and,
in particular, in HRPCa (30). Clinical studies testing
the currently available SSAs on patients with HRPCa
showed conflicting and non-conclusive results, proba-
bly due to the prevalent SS2R specificity of these
drugs. At this purpose, new targeted agents based on
different receptor affinity or more complex SSAs are
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under development to overcome the limitations of the
current molecules. Recently, mono- and bi-specific
SSAs (BIMs), as well as the pan-ligand pasireotide
(SOM 230) have been developed and their role in the
control of tumor growth has been explored in the last
years (Tab. 1). 
Aim of this review is to focus on the new knowledge
about the role of the SSRs and SSAs in the control of
PCa tumor growth. 
Prostate cancer
PCa is the most common tumor among men and, in
general, represents the second cause of death after
lung cancer (31). Age, race, familiarity, hormonal lev-
els, and environmental factors represent the most fre-
quent risk factors involved in PCa onset. In 70% of
cases, PCa is localized in the peripheral back area of
prostate gland and shows an androgen-dependent
phenotype. Histologically, majority of PCa are well-dif-
ferentiated adenocarcinomas (32, 33). Gleason score
is the most common method to classify PCa (34). Ac-
cording to this system, neoplasia are classified in five
groups on the basis of the glandular localization and
differentiation degree, being “grade 1” the well-differ-
entiated neoplasia and “grade 5” the non-differentiat-
ed tumours (showing no glandular differentiation).
This classification is extremely important in PCa since
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Table 1 - SRIF, SRIF analogs and SRIF/DA chimeric compounds: human SRIF receptor subtype (SSRs) speci-
ficity (IC50-nM).
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it affects the right therapeutic choice.
Besides surgical orchiectomy, the first-line standard
treatment for patients with hormone-sensitive disease
is an androgen deprivation obtained by using luteiniz-
ing hormone releasing-hormone (LHRH) agonists and
anti-androgens, alone or in combination. In general,
patients undergoing hormonal therapy respond to the
treatment lowering the plasmatic levels of prostate-
specific antigen (PSA) and reducing tumor mass. 
Neuroendocrine differentiation of prostate cancer
In a high percentage of PCa patients, responding to
hormonal treatment, after a period of quiescence cells
tend to lose their glandular differentiation and to ac-
quire a neuroendocrine phenotype releasing from an-
drogen dependence (HRPCa). This progression is re-
lated to a disease worsening and a bad prognosis
(32). The median survival for patients with HRPCa is
less than one year, and the available treatment op-
tions, including chemotherapy, are only palliative (35).
Neuroendocrine cells (NE) are scattered throughout
normal prostate and represent the third type of epithe-
lial cells (36). Similarly to NE cells in general, prostate
NE cells show an epithelial phenotype, the presence
of secretory granules, neuron specific enolase (NSE)
and cromogranin A (CgA) immunoreactivity etc. More-
over, they do not show a high proliferation rate and do
not express androgen receptors, indicating that they
can function independently from androgen regulation
(37). The function of NE cells in prostate gland is still
unclear but they are supposed to be involved in the
growth and differentiation of the normal gland, as well
as in the regulation of hormone secretion of the ma-
ture gland. 
Being independent from the androgenic regulation,
prostate NE cell growth is regulated by other growth
factors, the most representative being the epidermal
growth factor (EGF) (38). The main secretory product
of prostate NE cells is CgA, member of the acidic se-
cretion proteins. It has been demonstrated that high
plasmatic levels of CgA represent an important mark-
er of neuroendocrine differentiation of PCa (39).
Moreover, during PCa progression process, there is
either a selection of clones which escape the anti-an-
drogen therapy (androgen-independent) or an in-
crease of NE cells leading to a more aggressive tu-
mour with a worse prognosis (40). 
It has been also hypothesized that PCa NE cells do
not derive from normal NE cells but from a transforma-
tion of benign esocrine epithelial cells that occurs dur-
ing tumor progression (41). Androgen-independent
PCa tumor growth seems to be regulated by several
mechanisms, but it is principally modulated by the au-
tocrine-paracrine action of neuropeptides secreted by
NE cells (42). NE cells can also indirectly contribute to
“protect” neoplastic cell proliferation through an in-
crease of the anti-apoptotic activity mediated by the
iperexpression of bcl-2 (43). According to this concept,
NE cells produce a protective antiapoptotic effect for
neoplastic cells which can proliferate independently
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from androgenic stimulation. The evidence that in vi-
vo, the response of neoplastic cells to antineoplastic
therapies is directly influenced by microenvironment in
which they proliferate, has led to the concept of PCa
“antisurvival factor therapy”.
In this context, the characterization of SSR profile of
PCa cells could represent the basis for the develop-
ment of new therapeutic strategies using specific
SSAs. 
Somatostatin system
SRIF is a cyclic polypeptidic hormone largely ex-
pressed in hypothalamus which displays inhibitory
functions on hormone secretion (5-18) and cell prolif-
eration (14, 19, 20). SRIF acts on target cells through
its binding with five specific receptor subtypes code-
named SS1R-SS5R (21, 22, 44, 45). They belong to
the super family of G-protein coupled receptors
(GPCRs) and present seven transmembrane do-
mains. The binding of SRIF with SSRs inhibits the se-
cretion of a wide range of hormones, including the pi-
tuitary GH, PRL and TSH and mediates cytostatic ef-
fects and cell cycle arrest in G0/G1, or apoptosis of
tumoral cells both in vitro and in vivo (46) (Fig. 1). De-
pending on the different cell type, the binding of SRIF
with SSRs leads to an interaction of the activated re-
ceptors with specific G-proteins (22) activating differ-
ent intracellular pathways such as adenylyl and
guanylyl cyclases, phospholypase A2 and C, K+ and
Ca2+ channels, Na+-H+ pumps MAP kinase, thy-
rosin-phosphatase and Src (21, 44, 46-50). The enrol-
ment of different G-proteins and, consequently, the
activation of different intracellular pathways, repre-
sents the basis of the functional diversity of these re-
ceptors (51). In particular, hormone secretion is main-
ly regulated by the inhibition of cAMP production and
Ca2+ flows. Conversely, the cytostatic effect on cell
cycle is mediated by the activation of membrane
phosphotyrosine phosphatases (PTPases) (46, 49),
which, in turn, control the activity of a number of
downstream signaling molecules, particularly mitogen
activated protein kinase (MAPK, such as ERK1/2), cy-
clin-dependent kinase inhibitors (CDKI, such as
p27kip1 and p21cip1/waf1), and phosphatidylinositol
3-kinase (PI3K)/AKT signalling pathway (52). PTPs are
also able to alter growth factor (GF) signalling through
the selective dephosphorylation and inactivation of GF
receptors such as PDGF-R, VEGF-R2, insulin-R and
EGFR, indirectly inhibiting cell proliferation (49).
Recent studies demonstrated that the binding of SRIF
and SSAs to SS3R, and possibly to SS2R as well,
can induce apoptosis (53).
Although a 40-60% homology exists among SSRs,
each receptor subtype triggers different biologic func-
tions. Particularly, SS2R and SS5R are involved in the
control of GH secretion and SS5R is also able to mod-
ulate insulin and glucagone release. SS3R and, at a
less extent SS2R, can induce apoptosis, while SS1R,
SS4R, and SS5R are mainly involved in the inhibition
of cell proliferation, as well as in neurotransmission.
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Somatostatin receptors in prostate cancer
Besides pituitary, SSRs are heterogeneously ex-
pressed in numerous normal and neoplastic tissues
(20, 54), including prostate and PCa (23, 24, 26-29),
showing a tissue-specific distribution (54-57). More-
over, it has been demonstrated that almost all SRIF
target tissues express different receptor subtypes si-
multaneously (55). 
Several studies aimed to define the expression of
SSRs among epithelial and stromal cells in PCa tis-
sues both at mRNA and protein levels (23, 25), their
expression in the different stage of disease (26, 58)
and their modulation by hormonal treatment (30). In
any case, all results demonstrated a heterogeneous
SSR expression in PCa, either in terms of amount of
each specific receptor subtype in different stage of
disease or in terms of distribution among epithelial
and stromal cells. In detail, Mazzucchelli et al. de-
scribed that all five SSRs were expressed in cyto-
plasm of epithelial cell but only SS3R and SS4R were
expressed on cell membrane lowering their expres-
sion from normal-looking epithelium to high-grade
prostate intraepithelial neoplasia (HGPIN) and PCa
(30-90%). Moreover another study of the same group
demonstrated a further decrease of SS3R and SS4R
membrane expression (20-70%) from HGPIN/PCa
and HRPCa. Conversely, Sinisi et al. demonstrated
that SS3R mRNA (and, consequently, the protein) was
not expressed either in PCa or normal epithelial cells
cultured from PCa biopsies while SS2R was only ex-
pressed in epithelial cells of normal prostate tissue
and was absent in PCa (23). SS1R was only ex-
pressed in PCa epithelial cells while SS4R and SS5R
were expressed both in normal and PCa epithelial
cells. No SS1R, -2, -3, -4, and -5 were found in stro-
mal cells either in normal or in PCa (23). 
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A further different description of SSR expression and
distribution in PCa tissue comes from Dizey et al. This
group evaluated SSR expression in PCa tissues from
radical prostatectomy by immunohistochemistry de -
monstrating SS1R staining in tumor and neuroen-
docrine cells, SS2R staining in stromal cells, peritu-
moral blood vessels and tumor cells, SS3R staining in
benigne prostatic hyperplasia (BPH) and PCa epithe-
lial cells, SS4R strong immunostaining in PCa epithe-
lial cells and low expression in BPH. No SS5R expres-
sion was detected in PCa tissues (26). 
Moreover, recent studies on androgen-dependent and
-independent PCa cell lines demonstrated the consti-
tutive expression of specific SSRs (26) or all SSRs
(27), as well as the constitutive expression of SSR
hetero-dimers and SSR/dopamine receptor-2 (D2R)
dimers on PCa cell membrane (28) (Fig. 2), these lat-
ter once activated by specific ligands, displaying an
enhanced antiproliferative activity. Moreover, Ruscica
et al. demonstrated a modulation of SSR expression
depending on the presence of growth factors and/or
steroid hormones in the culture microenvironment
(27). In particular, these authors clearly demonstrated
that, mimicking a steroid deprivation by a switch of
FBS supplement from 10% (regular culture conditions)
to 2%, SS1R and SS3R were up-regulated (both at
mRNA and protein level), while no changes were ob-
served for SS2R and SS5R (27).
In these studies the only receptor subtype which was
demonstrated to be constantly expressed was SS1R.
Furthermore, Reubi et al. confirmed that SS1R is the
receptor subtype mainly expressed in PCa tissue
(59), whereas Kosari et al. demonstrated a signifi-
cant correlation between the amount of SS1R gene
expression and PCa progression. In detail, this group
showed that, among a number of candidate variably
Figure 1. Principal intracellular 
signalling cascades associated to
the binding of SRIF14 / analogs
with SRIF receptors. Red arrows
represent an inhibitory effect;
green arrows represent a stimula-
tory effect.
Legend: SSR: somatostatin recep-
tor; PTP: phosphothyrosine pho-
sphatases; IP3K: phosphatidylino-
sitol 3-kinase; RAF, MEK,ERK:
protein kinases belonging to
MAPK/ERK signal transduction
pathway; SHP-1 and SHP-2: Src
homology region 2 domain-contai-
ning phosphatase -1/-2;  NF-kB:
nuclear factor kappa-light-chain-
enhancer of activated B cells;
JNK: c-Jun N-terminal kinases. 
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overexpressed genes selected for their association
with aggressive PCa phenotype, the most prominent
candidate, besides genes already known to be relat-
ed to proliferation or cell cycle control, was SS1R
(60).
In this context, these findings could lead to consider
SS1R a good prognostic marker for PCa classification,
as well as a good target for the development of new
drugs acting through this receptor subtype.
Somatostatin analogues and prostate cancer 
After an excellent initial response to combined andro-
gen blockade therapy, in approximately 2-3  years,
most PCas progress to a hormone-refractory (HR)
stage with increased growth, invasion and malignancy
(61). Since the available treatment options for these
patients are palliative, new cancer therapies based on
peptide analogues could provide a promising strategy
for the management of advanced PCa (62). Among
the analogues of peptide hormones, SSAs have
gained the most attention because of their antineo-
plastic effects, such as decreased tumor cell growth
and angiogenesis, as well as an increased cancer cell
apoptosis (26) (Tab. 1).
First data on the parenteral use of octreotide, as an ad-
juvant therapy, demonstrated that treatment with this
SRIF analogue causes a moderate suppression of the
growth of transplanted Dunning R3327-H prostate tu-
mors in the rat (63). Regarding clinical studies, the re-
sults obtained in trials conducted on advanced HRPCa
patients using lanreotide are conflicting and not conclu-
sive. In 1995, a 12 weeks PhaseI-II study on 30 patients
with HRPCa, treated with a slow-release formulation of
lanreotide (30 mg i.m. weekly), showed that the perform-
ance status and bone pain were improved in 40% and
35% of patients, respectively, and 20% of them had a
decrease of at least 50% in PSA levels (64). Converse-
ly, a phase-I study conducted on 25 patients with
metastatic HRPCa treated with a continuous intra-
venous infusion of lanreotide, totalling 24 mg/day, did
not show any clinical response by either radiographic or
tumor marker criteria (65). In 2006 a randomized con-
trolled clinical trial on HRPCa patients demonstrated
that the combination of octreotide (20 mg i.m. every 28
days), oral dexamethasone (4 mg daily for 1 month) plus
zoledronate (a bisphosphonate interfering with bone re-
modeling) vs zoledronate alone, resulted in a better out-
come with respect to median progression-free survival,
median PCa-specific overall survival and median dura-
tion of bone pain improvement (66).
Since peptide receptors are often expressed in many
primary tumors, they can be targeted by a specific
peptide as well as by different labelled analogs (67).
Hence, peptides as potential therapeutics or drug-de-
livering vehicles, possess a number of attractive char-
acteristics such as rapid circulatory clearance and
good tumor tissue-penetrating ability. In this context,
the use of the hybrid analogue AN-238, consisting of
2-pyrrolinodoxorubicin (AN-201) and carrier RC-121,
has been shown to be highly effective in SS2R-posi-
tive anaplastic Dunning R-3327 AT-1 rat PCa at a non-
toxic dose. In contrast, the cytotoxic radical and the
carrier protein, administered separately, were ineffec-
tive and toxic (68). In line with these data, a recent in
vitro study reported that lanreotide could interact with
docetaxel in HRPCa cells, with possible explanatory
mechanisms involving the regulation of the interaction
of P-glycoprotein-mediated docetaxel through lan-
reotide (69). This latter evidence was corroborate by
the same authors which also demonstrated that oc-
treotide and docetaxel combination increase HRPCa
cell death through cell cycle regulation and induction
of apoptosis (70).
Figure 2. Schematic representa-
tion of SSR/D2R homo- and 
hetero-dimerization. In order to
simplify the figure, only SS2R,
SS5R and D2R were considered.
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The most frequent problem arising from PCa is its
propensity to metastasize following local invasion, one
of the early steps in tumor spreading. In this context,
octreotide has been shown to inhibit the migration and
invasion aptitudes of DU-145 and PC-3 human andro-
gen-independent cells (71). Nevertheless, the multi-
step process of invasion is supported by the synthesis
of new proteins, lipids, and nucleic acids which is crit-
ical for cell growth and division. Interestingly, Yan
demonstrated that smsDX SRIF derivate inhibited the
invasiveness of PCa cells by deregulating metabolic
enzymes (glycolysis, tricarboxylic acid cycle, pentose
phosphate, glutaminolysis and oxidative phosphoryla-
tion) and proteins which are involved in the process of
HRPCa cell invasiveness and survival (72).
As already mentioned above, SSRs can be expressed
on cell membrane of target tissues not only as
monomers but also as omo- or hetero-dimers. Based
on this novelty in the field of SSR, recent studies
aimed to evaluate the activity of SSR dimers in regu-
lating tumor cell proliferation. At this purpose, an in vit-
ro study by Ruscica et al. on the human-androgen de-
pendent LNCaP cell line demonstrated that the
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SS2R/SS5R bi-specific compound, BIM-23244, was
able to significantly induce/stabilize SS2R/SS5R
dimer and modulate IGF-I secretion (Fig. 3), thus in-
ducing a set of complementary favorable events in
terms of antiproliferative activity (27). Moreover, the
same group demonstrated that, besides the
SS2R/SS5R-driven antiproliferative/antisecretive ac-
tions, only the SS1R mono-specific compound, BIM-
23926, was able to significantly inhibit PCa cell prolif-
eration (-28/-36% vs. untreated cells) even at low dos-
es. This effect was demonstrated not only in the an-
drogen-dependent PCa cell line LNCaP but also in the
androgen-independent PCa cell lines, DU-145 and
PC-3 (Ruscica et al., unpublished data) ascribing to
SS1R a crucial role in the control of cell proliferation in
these tumor cells. 
Similarly, another study investigated the effect of a
new generation of chimeric “dopastatins” in LNCaP
cells endogenously expressing SSRs and D2R, ob-
serving, for the first time, a direct and significant posi-
tive correlation between the amount of ligand induced
SS5R/D2R dimers and the magnitude of the antiprolif-
erative effect. 
Figure 3. Effect of SSA treatment on growth factor secretion in LNCaP cells. Cells were treated for 48h with the SS2R/SS5R
bi-specific compound BIM-23244, SS1R/SS2R bi-specific compound BIM-23704 and SS1R mono-specific compound BIM-
23926 (all compounds 10-8 M). After the incubation time, conditioned media were collected and analyzed by protein array
method. In the upper part of the figure all growth factors are listed in the same sequence as they appear, as spot, in the blots
below. At the bottom of the figure, histograms represent the densitometric analysis of IGF-I, IGF-II and IGFBP-2 after BIM
treatment, expressed as delta% vs untreated cells (CTR). 
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Conclusion and new prospectives
In this review, we pointed out that SSRs expression in
PCa can vary depending on the different stage of dis-
ease, hormonal treatment and presence of factors in
the microenvironment able to modify quantitatively
and, perhaps also qualitatively, SSR profile. Moreover,
all studies evaluating the effect of the commercially
available SSAs (commonly used in clinical practice) in
the control of PCa growth, showed inconclusive re-
sults so far, probably due to the prevalent SS2R speci-
ficity of these drugs. In this context, according to the
recent data demonstrating either the inefficacy of
SS2R monospecific compounds in the inhibition of cell
proliferation or the significant effect of a SS1R and
SS2R/SS5R specific compounds in androgen-de-
pendent and -independent PCa cell lines, SS1R and
SS2R/SS5R dimer have been emerging as the most
functional and representative SSRs in PCa. Moreover,
regarding SS1R, which gene has been demonstrated
to be up-regulated in the progression of PCa towards
a more aggressive phenotype, could represent a new
target for the development of innovative treatment
strategies. 
References
1. Dayyani F, Gallick GE, Logothetis CJ, Corn PG.
Novel therapies for metastatic castrate-resistant
prostate cancer. J Natl Cancer Inst 2011; 103(22):
1665-75.
2. Xu Y, Jiang YF, Wu B. New agonist- and antagonist-
based treatment approaches for advanced prostate
cancer. J Int Med Res 2012; 40(4): 1217-26.
3. Toulis KA, Goulis DG, Msaouel P, Koutsilieris M.
Dexamethasone plus somatostatin-analog manipu-
lation as bone metastasis microenvironment-target-
ing therapy for the treatment of castration-resistant
prostate cancer: a meta-analysis of uncontrolled
studies. Anticancer Res 2012; 32(8): 3283-9.
4. Lattanzio L, Tonissi F, Monteverde M, Milano G,
Merlano MC, Lo Nigro C. Differential molecular
mechanism of docetaxel-octreotide combined treat-
ment according to the docetaxel-resistance status
in PC3 prostate cancer cells. Anticancer Drugs
2013; 24(2): 120-30.
5. Konturek SJ, Tasler J, Obtulowicz W, Coy DH,
Schally AV. Effect of growth hormone-release in-
hibiting hormone on hormones stimulating exocrine
pancreatic secretion. J Clin Invest 1976; 58(1): 1-6.
6. Raptis S, Schlegel W, Lehmann E, Dollinger HC,
Zoupas C. Effects of somatostatin on the exocrine
pancreas and the release of duodenal hormones.
Metabolism 1978; 27(9 Suppl 1): 1321-8.
7. Zabel BU, Naylor SL, Sakaguchi AY, Bell GI, Shows
TB. High-resolution chromosomal localization of hu-
man genes for amylase, proopiomelanocortin, so-
matostatin, and a DNA fragment (D3S1) by in situ
hybridization. Proc Natl Acad Sci U S A 1983;
80(22): 6932-6.
8. Kraenzlin ME, Wood SM, Neufeld M, Adrian TE,
M. Arvigo et al.
8 Reviews in Endocrinology and Metabolism 2013; 1 (1): 2-10
Bloom SR. Effect of long acting somatostatin-ana-
logue, SMS 201 995, on gut hormone secretion in
normal subjects. Experientia 1985; 41(6): 738-40.
9. Hugues JN, Epelbaum J, Voirol MJ, Sebaoun J, Ko-
rdon C, Enjalbert A. Involvement of endogenous so-
matostatin in the regulation of thyrotroph secretion
during acute and chronic changes in diet. Neuroen-
docrinology 1986; 43(3): 435-9.
10. Williams G, Fuessl H, Kraenzlin M, Bloom SR. Post-
prandial effects of SMS 201-995 on gut hormones
and glucose tolerance. Scand J Gastroenterol Suppl
1986; 119: 73-83.
11. Chen C, Israel JM, Vincent JD. Electrophysiological
responses to somatostatin of rat hypophysial cells in
somatotroph-enriched primary cultures. J Physiol
1989; 408: 493-510.
12. Bertherat J, Bluet-Pajot MT, Epelbaum J. Neuroen-
docrine regulation of growth hormone. Eur J En-
docrinol 1995; 132(1): 12-24.
13. Le Romancer M, Cherifi Y, Levasseur S, Laigneau JP,
Peranzi G, Jais P, et al. Messenger RNA expression
of somatostatin receptor subtypes in human and rat
gastric mucosae. Life Sci 1996; 58(13): 1091-8.
14. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S,
Morgan B, et al. Somatostatin receptor subtype
specificity in human fetal pituitary cultures. Differen-
tial role of SS2R and SS5R for growth hormone,
thyroid-stimulating hormone, and prolactin regula-
tion. J Clin Invest 1997; 99(4): 789-98.
15. Chen C. G(o)2 and Gi3 proteins mediate the action
of somatostatin on membrane Ca2+ and K+ cur-
rents in ovine pituitary somatotrophs. Clin Exp Phar-
macol Physiol 1997; 24(8): 639-45.
16. Bluet-Pajot MT, Epelbaum J, Gourdji D, Hammond C,
Kordon C. Hypothalamic and hypophyseal regulation
of growth hormone secretion. Cell Mol Neurobiol
1998; 18(1): 101-23.
17. Kreienkamp HJ, Akgun E, Baumeister H, Meyerhof
W, Richter D. Somatostatin receptor subtype 1 mod-
ulates basal inhibition of growth hormone release in
somatotrophs. FEBS Lett 1999; 462(3): 464-6.
18. Rohrer SP Schaeffer JM. Identification and charac-
terization of subtype selective somatostatin receptor
agonists. J Physiol Paris 2000; 94(3-4): 211-5.
19. Florio T. Molecular mechanisms of the antiprolifera-
tive activity of somatostatin receptors (SSRs) in neu-
roendocrine tumors. Front Biosci 2008; 13: 822-40.
20. Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P.
Somatostatin, somatostatin analogs and somato-
statin receptor dynamics in the biology of cancer
progression. Curr Mol Med 2013; 13(4): 555-71.
21. Patel YC. Somatostatin and its receptor family. Front
Neuroendocrinol 1999; 20(3): 157-98.
22. Moller LN, Stidsen CE, Hartmann B, Holst JJ. So-
matostatin receptors. Biochim Biophys Acta 2003;
1616(1): 1-84.
23. Sinisi AA, Bellastella A, Prezioso D, Nicchio MR,
Lotti T, Salvatore M, et al. Different expression pat-
terns of somatostatin receptor subtypes in cultured
epithelial cells from human normal prostate and
prostate cancer. J Clin Endocrinol Metab 1997; 82(8):
2566-9.
©
 C
IC
 Ed
izi
on
i I
nt
e
na
zi
na
li
24. Benali N, Ferjoux G, Puente E, Buscail L, Susini C.
Somatostatin receptors. Digestion 2000; 62 Suppl 1:
27-32.
25. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG,
Plonowski A. High expression of somatostatin re-
ceptors and messenger ribonucleic acid for its recep-
tor subtypes in organ-confined and locally advanced
human prostate cancers. J Clin Endocrinol Metab
2000; 85(7): 2564-71.
26. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V,
Hansson J, et al. Localization and mRNA expression
of somatostatin receptor subtypes in human prosta-
tic tissue and prostate cancer cell lines. Urol Oncol
2002; 7(3): 91-8.
27. Ruscica M, Arvigo M, Gatto F, Dozio E, Feltrin D,
Culler MD, et al. Regulation of prostate cancer cell
proliferation by somatostatin receptor activation. Mol
Cell Endocrinol 2010; 315(1-2): 254-62.
28. Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Al-
bertelli M, et al. Somatostatin and dopamine recep-
tor interaction in prostate and lung cancer cell lines.
J Endocrinol 2010; 207(3): 309-17.
29. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng
L, Di Primio R, Bono A, et al. Immunohistochemical
expression and localization of somatostatin receptors
in normal prostate, high grade prostatic intraepithe-
lial neoplasia and prostate cancer and its many faces.
J Biol Regul Homeost Agents 2012; 26(2): 181-92.
30. Mazzucchelli R, Morichetti D, Santinelli A, Scarpelli
M, Bono AV, Lopez-Beltran A, et al. Immunohisto-
chemical expression and localization of somatostatin
receptor subtypes in androgen ablated prostate can-
cer. Cell Oncol (Dordr) 2011; 34(3): 235-43.
31. Boring CC, Squires TS, Tong T, Montgomery S. Can-
cer statistics, 1994. CA Cancer J Clin 1994; 44(1): 7-
26.
32. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular
biology of prostatic intraepithelial neoplasia. Prostate
1996; 29(2): 117-34.
33. Mostofi FK, Davis CJ Jr., Sesterhenn IA. Pathology
of carcinoma of the prostate. Cancer 1992; 70(1
Suppl): 235-53.
34. Deshmukh N, Foster CS. Grading prostate cancer.
Pathology of the Prostate1997: Philadelphia: WB
Saunders.
35. Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi
K. Inhibition of PC-3 human androgen-independent
prostate cancer and its metastases by cytotoxic so-
matostatin analogue AN-238. Cancer Res 1999;
59(8): 1947-53.
36. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer
S, Grimelius L. Peptide-hormone- and serotonin-im-
munoreactive cells in normal and hyperplastic prostate
glands. Pathol Res Pract 1986; 181(6): 675-83.
37. Nakada SY, di Sant’Agnese PA, Moynes RA, Hi-
ipakka RA, Liao S, Cockett AT, et al. The androgen
receptor status of neuroendocrine cells in human
benign and malignant prostatic tissue. Cancer Res
1993; 53(9): 1967-70.
38. Iwamura M, Koshiba K, Cockett AT. Receptors for
BPH growth factors are located in some neuroen-
docrine cells. Prostate Suppl 1998; 8: 14-7.
Somatostatin and prostate cancer: role of somatostatin receptors in the control of tumor growth
Reviews in Endocrinology and Metabolism 2013; 1 (1): 2-10 9
39. Berruti A, Mosca A, Tucci M, Terrone C, Torta M,
Tarabuzzi R, et al. Independent prognostic role of cir-
culating chromogranin A in prostate cancer patients
with hormone-refractory disease. Endocr Relat Can-
cer 2005; 12(1): 109-17.
40. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The
neuroendocrine phenotype in prostate cancer: basic
and clinical aspects. J Endocrinol Invest 2005; 28(11
Suppl International): 141-5.
41. Bonkhoff H, Stein U, Remberger K. Multidirectional
differentiation in the normal, hyperplastic, and neo-
plastic human prostate: simultaneous demonstra-
tion of cell-specific epithelial markers. Hum Pathol
1994; 25(1): 42-6.
42. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco
F, Di Silverio F. New perspective in the management
of neuroendocrine differentiation in prostate adeno-
carcinoma. Int J Clin Pract 2006; 60(4): 462-70.
43. Anvari K, Seilanian Toussi M, Kalantari M, Naseri S,
Karimi Shahri M, Ahmadnia H, et al. Expression of
Bcl-2 and Bax in advanced or metastatic prostate
carcinoma. Urol J 2012; 9(1): 381-8.
44. Lamberts SW, van der Lely AJ, Hofland LJ. New so-
matostatin analogs: will they fulfil old promises? Eur
J Endocrinol 2002; 146(5): 701-5.
45. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez
F, Rochaix P, et al. Signal transduction of somato-
statin receptors negatively controlling cell prolifera-
tion. J Physiol Paris 2000; 94(3-4): 205-10.
46. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer
D, Bruns C. Opportunities in somatostatin research:
biological, chemical and therapeutic aspects. Nat
Rev Drug Discov 2003; 2(12): 999-1017.
47. Lamberts SW, Krenning EP, Klijn JG, Reubi JC. Clin-
ical applications of somatostatin analogs. Trends En-
docrinol Metab 1990; 1(3): 139-44.
48. Lamberts SW, van der Lely AJ, de Herder WW,
Hofland LJ. Octreotide. N Engl J Med 1996; 334(4):
246-54.
49. Florio T. Somatostatin/somatostatin receptor sig-
nalling: phosphotyrosine phosphatases. Mol Cell En-
docrinol 2008; 286(1-2): 40-8.
50. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Riv-
ier J, et al. Hypothalamic polypeptide that inhibits the
secretion of immunoreactive pituitary growth hor-
mone. Science 1973; 179(4068): 77-9.
51. Law SF, Woulfe D, Reisine T. Somatostatin receptor
activation of cellular effector systems. Cell Signal
1995; 7(1): 1-8.
52. Theodoropoulou M, Zhang J, Laupheimer S, Paez-
Pereda M, Erneux C, Florio T, et al. Octreotide, a so-
matostatin analogue, mediates its antiproliferative
action in pituitary tumor cells by altering phos-
phatidylinositol 3-kinase signaling and inducing Zac1
expression. Cancer Res 2006; 66(3): 1576-82.
53. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M,
Teti C, et al. The clinical-molecular interface of so-
matostatin, dopamine and their receptors in pituitary
pathophysiology. J Mol Endocrinol 2009; 42(5): 361-
70.
54. Florio T, Montella L, Corsaro A, De Chiara A, Apice
G, Fazioli F, et al. In vitro and in vivo expression of
©
 C
IC
 Ed
iz
i I
ter
n
zio
na
li
M. Arvigo et al.
10 Reviews in Endocrinology and Metabolism 2013; 1 (1): 2-10
somatostatin receptors in intermediate and malignant
soft tissue tumors. Anticancer Res 2003; 23(3B):
2465-71.
55. Patel YC, Srikant CB. Somatostatin receptors. Trends
Endocrinol Metab 1997; 8(10): 398-405.
56. Reisine T. Somatostatin receptors. Am J Physiol
1995; 269(6 Pt 1): G813-20.
57. Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F,
Ameri P, Colao A, et al. Immunohistochemical local-
ization and quantitative expression of somatostatin
receptors in normal human spleen and thymus: Im-
plications for the in vivo visualization during somato-
statin receptor scintigraphy. J Endocrinol Invest 2012;
35(5): 528-34.
58. Mazzucchelli R, Morichetti D, Scarpelli M, Bono AV,
Lopez-Beltran A, Cheng L, et al. Somatostatin recep-
tor subtypes in hormone-refractory (castration-re-
sistant) prostatic carcinoma. Asian J Androl 2011;
13(2): 242-7.
59. Reubi JC, Waser B, Schaer JC, Markwalder R. So-
matostatin receptors in human prostate and prostate
cancer. J Clin Endocrinol Metab 1995; 80(9): 2806-
14.
60. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee
EW, Kube DM, et al. Identification of prognostic bio-
markers for prostate cancer. Clin Cancer Res 2008;
14(6): 1734-43.
61. Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder
FH, Sternberg C, et al. Castration-resistant prostate
cancer: from new pathophysiology to new treatment
targets. Eur Urol 2009; 56(4): 594-605.
62. Limonta P, Manea M. Gonadotropin-releasing hor-
mone receptors as molecular therapeutic targets in
prostate cancer: Current options and emerging
strategies. Cancer Treat Rev 2013.
63. Siegel RA, Tolcsvai L, Rudin M. Partial inhibition of
the growth of transplanted dunning rat prostate tu-
mors with the long-acting somatostatin analogue
sandostatin (SMS 201-995). Cancer Res 1988;
48(16): 4651-5.
64. Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-
Esquerre F, Housset M. Phase I-II study of the so-
matostatin analogue lanreotide in hormone-refractory
prostate cancer. Cancer Chemother Pharmacol
1995; 36(3): 259-62.
65. Figg WD, Thibault A, Cooper MR, Reid R, Headlee
D, Dawson N, et al. A phase I study of the somato-
statin analogue somatuline in patients with metasta-
tic hormone-refractory prostate cancer. Cancer 1995;
75(8): 2159-64.
66. Mitsiades CS, Bogdanos J, Karamanolakis D, Milathi-
anakis C, Dimopoulos T, Koutsilieris M. Random-
ized controlled clinical trial of a combination of so-
matostatin analog and dexamethasone plus
zoledronate vs. zoledronate in patients with androgen
ablation-refractory prostate cancer. Anticancer Res
2006; 26(5B): 3693-700.
67. Ruscica M, Dozio E, Motta M, Magni P. Relevance of
the neuropeptide Y system in the biology of cancer
progression. Curr Top Med Chem 2007; 7(17): 1682-
91.
68. Koppan M, Nagy A, Schally AV, Arencibia JM,
Plonowski A, Halmos G. Targeted cytotoxic analogue
of somatostatin AN-238 inhibits growth of androgen-
independent Dunning R-3327-AT-1 prostate cancer
in rats at nontoxic doses. Cancer Res 1998; 58(18):
4132-7.
69. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano
G, Merlano M. The combination of docetaxel and the
somatostatin analogue lanreotide on androgen-inde-
pendent docetaxel-resistant prostate cancer: exper-
imental data. BJU Int 2008; 102(5): 622-7.
70. Lo Nigro L. Biology of childhood acute lymphoblas-
tic leukemia. J Pediatr Hematol Oncol 2013; 35(4):
245-52.
71. Tang X, Takekoshi S, Itoh J, Umemura S, Shoji S,
Terachi T, et al. Somatostatin analogue inhibits the
mobility of prostate carcinoma cells: a new therapeu-
tic method for advanced prostate carcinoma. Int J
Oncol 2010; 37(5): 1077-83.
72. Yan L, Xing Z, Guo Z, Fang Z, Jiao W, Guo X, et al.
Somatostatin derivative (smsDX) targets cellular me-
tabolism in prostate cancer cells after androgen dep-
rivation therapy. PLoS One 2013; 8(2): e55790.
©
 C
IC
 Ed
izi
i I
ter
na
zi
na
li
